Very-low-dose combination of XXXX and @entity7486 : efficacy on blood pressure and target-organ damage.

@entity5394 @entity1 @entity4688 @entity101 @entity7486 @entity6 @entity349 @entity13519 @entity2165 @entity551 @entity4687
OBJECTIVE: To review the safety and efficacy of the very-low-dose combination of @entity4687 2 mg and @entity7486 0.625 mg ( @entity5394 /Ind0.625) in essential @entity101 , in relation to blood pressure control and target-organ damage. STUDY SELECTION: We included in this review several double-blind, randomized studies in @entity101 @entity1 , including five main studies from the European registration file and two clinical trials on regression of target-organ damage [large artery stiffness: the Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind Study (REASON); microalbuminuria in @entity1 with type 2 @entity6 : the Preterax in Albuminuria Regression (PREMIER) study]. MAIN OUTCOME MEASURES: Systolic ( @entity13519 ) and @entity551 measured at trough with a @entity349 sphygmomanometer, an automatic device (OMRON), and 24-h ambulatory blood pressure measurements (ABPM). Arterial stiffness, assessed from pulse wave velocity measurement and augmentation index (REASON study). Microalbuminuria (PREMIER study). RESULTS: The @entity5394 /Ind0.625 combination was selected from the dose-finding studies. Twelve weeks after the @entity1 were assigned to study groups, the reductions in @entity13519 , measured with an OMRON device, were 12.3 +/- 15.0 mmHg with @entity5394 /Ind0.625, 8.0 +/- 16.5 mmHg with @entity4687 2 mg (P = 0.001), 9.4 +/- 14.3 mmHg with @entity7486 0.625 mg (P = 0.023) and 2.1 +/- 16.8 mmHg with placebo (P < 0.001) (mean +/- SD; all P values are for comparisons with @entity5394 /Ind0.625). The reductions in DBP were 6.8 +/- 9.2 mmHg, 5.0 +/- 9.5 mmHg (P = 0.02), 4.7 +/- 8.2 mmHg (P = 0.004) and 2.4 +/- 9.6 mmHg (P < 0.001) in the @entity5394 /Ind0.625, @entity4687 2 mg, @entity7486 0.625 mg and placebo groups, respectively. During the long-term study, among 235 @entity1 who achieved initial blood pressure normalization with the fixed combination, 79.8% sustained their normalized status over 1 year, with no significant difference regarding safety criteria. During the REASON study, Per/Ind reduced pulse wave velocity to a similar extent as @entity2165 , and augmentation index to a greater extent. During the PREMIER study, Per/Ind reduced microalbuminuria to a greater extent than did @entity4688 . CONCLUSIONS: The proven efficacy on blood pressure and regression of target-organ damage with a good safety profile confirm that the new fixed-low-dose combination @entity5394 /Ind0.625 is a valuable option in the first-line treatment of @entity101 .
